Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ECS Botanics HoldingsASX:ECS -8.33% EV-to-EBITDA is 23.23 as of Sep. 10, 2026. The stock has 9 warning signs investors should review. Among 727 Drug Manufacturers companies, ECS Botanics Holdings ranks worse than 74.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ECS Botanics Holdings's enterprise value is A$13.52 Mil.
ECS Botanics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.58 Mil. Therefore, ECS Botanics Holdings's EV-to-EBITDA for today is 23.23.
The historical rank and industry rank for ECS Botanics Holdings's EV-to-EBITDA or its related term are showing as below:
ASX:ECS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -478.57 Med: -3.6 Max: 27.36
Current: 23.23
During the past 13 years, the highest EV-to-EBITDA of ECS Botanics Holdings was 27.36. The lowest was -478.57. And the median was -3.60.
ASX:ECS's EV-to-EBITDA is ranked worse than 74.55% of 727
companies
in the Drug Manufacturers industry
Industry Median: 13.34
vs ASX:ECS: 23.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ECS Botanics Holdings's PE Ratio (TTM) for today is calculated as:
ECS Botanics Holdings's share price for today is A$0.0055.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ECS Botanics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was A$-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
ECS Botanics Holdings EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ECS Botanics Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ECS Botanics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ECS Botanics Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ECS Botanics Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ECS Botanics Holdings's EV-to-EBITDA falls into.
ECS Botanics Holdings's current Enterprise Value is A$13.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ECS Botanics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ECS Botanics Holdings (ASX:ECS) has a EV-to-EBITDA of 23.23 as of Sep. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ECS Botanics Holdings. According to the industry distribution chart, ECS Botanics Holdings ranks #542 out of 727 companies in the Drug Manufacturers industry, placing it in the top 74.6%.
Is ECS Botanics Holdings' EV-to-EBITDA too high?
ECS Botanics Holdings' current EV-to-EBITDA is 23.23. The Drug Manufacturers industry median EV-to-EBITDA is 13.34. ECS Botanics Holdings' value of 23.23 is 74.1% above this industry median. Based on the distribution chart, ECS Botanics Holdings ranks #542 out of 727 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does ECS Botanics Holdings' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ECS Botanics Holdings ranks #542 out of 727 companies for EV-to-EBITDA. This places ECS Botanics Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.34. ECS Botanics Holdings' value of 23.23 is 74.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.34, based on 727 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ECS Botanics Holdings's current EV-to-EBITDA of 23.23 is 74.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ECS Botanics Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ECS Botanics Holdings's current EV-to-EBITDA is 23.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ECS Botanics Holdings stock overvalued right now?
ECS Botanics Holdings (ASX:ECS) has a current EV-to-EBITDA of 23.23. The current EV-to-EBITDA is 23.23 and 74.1% above the Drug Manufacturers industry median of 13.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ECS Botanics Holdings (ASX:ECS), the current EV-to-EBITDA is 23.23 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. The company utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, the company provides quality, affordable medicinal cannabis, supplying both local and overseas markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ECS has been successfully added to your 
